Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · IEX Real-Time Price · USD
16.59
+1.19 (7.73%)
At close: May 17, 2024, 4:00 PM
16.84
+0.25 (1.51%)
After-hours: May 17, 2024, 6:10 PM EDT
Nurix Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Nurix Therapeutics stock have an average target of 22.22, with a low estimate of 10 and a high estimate of 31. The average target predicts an increase of 33.94% from the current stock price of 16.59.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRIX stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 3 |
| Buy | 5 | 5 | 4 | 3 | 4 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 7 | 6 | 7 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $27 | Strong Buy | Maintains | $27 | +62.75% | May 15, 2024 |
| Needham | Needham | Strong Buy Reiterates $31 | Strong Buy | Reiterates | $31 | +86.86% | May 14, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $20 | Buy | Initiates | $20 | +20.55% | May 14, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +38.64% | Apr 11, 2024 |
| Baird | Baird | Buy Maintains $24 → $25 | Buy | Maintains | $24 → $25 | +50.69% | Apr 11, 2024 |
Financial Forecast
Revenue This Year
70.53M
from 76.99M
Decreased by -8.39%
Revenue Next Year
76.39M
from 70.53M
Increased by 8.30%
EPS This Year
-3.20
from -2.65
EPS Next Year
-3.17
from -3.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 153.3M | 211.1M | 339.2M | 207.4M | 367.5M |
| Avg | 70.5M | 76.4M | 138.5M | 130.2M | 298.9M |
| Low | 49.3M | 32.7M | 50.3M | 73.8M | 214.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 99.1% | 199.2% | 344.0% | 49.7% | 182.2% |
| Avg | -8.4% | 8.3% | 81.4% | -6.0% | 129.5% |
| Low | -35.9% | -53.6% | -34.1% | -46.7% | 65.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.13 | -1.37 | -0.67 | -2.38 | -1.06 |
| Avg | -3.20 | -3.17 | -3.27 | -3.01 | -1.53 |
| Low | -3.72 | -4.84 | -5.54 | -3.29 | -1.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.